Adaptimmune loses $3B biobucks pact with Genentech
Roche’s Genentech has broken off its collaboration and license agreement on off-the-shelf T cell therapies with Adaptimmune.
The pullback means Adaptimmune could
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
